Matinas BioPharma Holdings (MTNB) FCF Margin (2015 - 2023)
Matinas BioPharma Holdings (MTNB) posted quarterly FCF Margin of 304.16% for Q2 2023, up 18370.0% year-over-year from N/an in Q2 2022, and up 72.09% quarter-over-quarter from 1089.87% in Q1 2023.
Matinas BioPharma Holdings (MTNB) FCF Margin (2015 - 2023) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported FCF Margin for 8 consecutive years, with 304.16% the latest figure, recorded in Q2 2023.
- In Q2 2023, FCF Margin rose 18370.0% year-over-year to 304.16%; the TTM figure through Dec 2023 stood at 1395.44% (down 76671.0% YoY), while the FY2023 annual figure was 1413.87%, down 78501.0% from the prior year.
- FCF Margin advanced to 304.16% in Q2 2023 per MTNB's latest filing, from 1089.87% in the prior quarter.
- Across five years, FCF Margin topped out at 1199121.32% in Q4 2021 and bottomed at 13953.48% in Q1 2021.
- Historically, FCF Margin has averaged 118109.97% across 5 years, with a median of 489.46% in 2022.
- Annual changes were most pronounced in 2021 — FCF Margin soared 119226551 bps — and 2022, when it plunged 119952969 bps.
- Matinas BioPharma Holdings' FCF Margin stood at 2688.53% in 2019, then surged by 355 bps to 6855.81% in 2020, then surged by 17391 bps to 1199121.32% in 2021, then sank by 100 bps to 408.37% in 2022, then climbed by 26 bps to 304.16% in 2023.
- Business Quant data shows MTNB's FCF Margin at 304.16% in Q2 2023, 1089.87% in Q1 2023, and 408.37% in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 22.62% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -22.35% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 70.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 41.07% |
| 10 | Matinas BioPharma Holdings | 1.19 Mn | 375,426.61 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -304.16% |
| Mar 31, 2023 | -1,089.87% |
| Dec 31, 2022 | -408.37% |
| Sep 30, 2022 | -491.06% |
| Jun 30, 2022 | -487.86% |
| Dec 31, 2021 | 1,199,121.32% |
| Mar 31, 2021 | -13,953.48% |
| Dec 31, 2020 | 6,855.81% |
| Sep 30, 2020 | -5,454.07% |
| Jun 30, 2019 | -2,688.53% |
| Jun 30, 2018 | -2,691.40% |
| Mar 31, 2018 | -9,712.55% |
| Dec 31, 2017 | -4,528.82% |
| Sep 30, 2017 | -6,277.44% |
| Jun 30, 2017 | -8,301.12% |
| Mar 31, 2017 | -20,253.41% |
| Sep 30, 2015 | -3,630.01% |
| Jun 30, 2015 | -2,922.68% |
| Mar 31, 2015 | -4,038.57% |